GPNMB expression in uveal melanoma: a potential for targeted therapy - PubMed (original) (raw)
GPNMB expression in uveal melanoma: a potential for targeted therapy
Michelle D Williams et al. Melanoma Res. 2010 Jun.
Abstract
Uveal melanoma is an aggressive disease without effective adjuvant therapy for metastases. Despite genomic differences between cutaneous and uveal melanomas, therapies based on shared biological factors could be effective against both tumor types. High expression of glycoprotein-NMB (GPNMB) in cutaneous melanomas led to the development of CDX-011 (glembatumumab vedotin), a fully human monoclonal antibody against the extracellular domain of GPNMB conjugated to the cytotoxic microtubule toxin monomethylauristatin E. Ongoing phase II trials suggest that CDX-011 has activity against advanced cutaneous melanomas. To determine the potential role of CDX-011 in uveal melanomas, we studied their GPNMB expression. Paraffin-embedded tissues from 22 uveal melanomas treated by enucleation from 2004-2007 at one institution were evaluated immunohistochemically for expression of GPNMB using biotinylated CDX-011 (unconjugated) antibody. Melanoma cells were evaluated for percentage and intensity of expression. Spectral imaging was used in one case with high melanin content. Clinical data were reviewed. Twelve women and 10 men with a median age of 58.7 years (range: 28-83 years) were included. Eighteen of 21 tumors evaluated immunohistochemically (85.7%) expressed GPNMB in 10-90% of tumor cells with variable intensity (5 tumors, 1+; 11, 2+; and 2, 3+). Eleven of 18 tumors (61.1%) expressed GPNMB in >or=50% of cells. Spectral imaging showed diffuse CDX-011 (unconjugated) reactivity in the remaining case. Uveal melanoma, like cutaneous melanoma, commonly expresses GPNMB. Ongoing clinical trials of CDX-011 should be extended to patients with metastatic uveal melanoma to determine potential efficacy in this subset of patients with melanoma.
Similar articles
- Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer.
Rose AA, Grosset AA, Dong Z, Russo C, Macdonald PA, Bertos NR, St-Pierre Y, Simantov R, Hallett M, Park M, Gaboury L, Siegel PM. Rose AA, et al. Clin Cancer Res. 2010 Apr 1;16(7):2147-56. doi: 10.1158/1078-0432.CCR-09-1611. Epub 2010 Mar 9. Clin Cancer Res. 2010. PMID: 20215530 - Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target.
All-Ericsson C, Girnita L, Seregard S, Bartolazzi A, Jager MJ, Larsson O. All-Ericsson C, et al. Invest Ophthalmol Vis Sci. 2002 Jan;43(1):1-8. Invest Ophthalmol Vis Sci. 2002. PMID: 11773005 - Targeted therapy for uveal melanoma.
Triozzi PL, Eng C, Singh AD. Triozzi PL, et al. Cancer Treat Rev. 2008 May;34(3):247-58. doi: 10.1016/j.ctrv.2007.12.002. Epub 2008 Jan 28. Cancer Treat Rev. 2008. PMID: 18226859 Review. - Gpnmb/osteoactivin, an attractive target in cancer immunotherapy.
Zhou LT, Liu FY, Li Y, Peng YM, Liu YH, Li J. Zhou LT, et al. Neoplasma. 2012;59(1):1-5. doi: 10.4149/neo_2012_001. Neoplasma. 2012. PMID: 22017590 Review.
Cited by
- Expression and immunolocalization of Gpnmb, a glioma-associated glycoprotein, in normal and inflamed central nervous systems of adult rats.
Huang JJ, Ma WJ, Yokoyama S. Huang JJ, et al. Brain Behav. 2012 Mar;2(2):85-96. doi: 10.1002/brb3.39. Brain Behav. 2012. PMID: 22574278 Free PMC article. - The potential of GPNMB as novel neuroprotective factor in amyotrophic lateral sclerosis.
Tanaka H, Shimazawa M, Kimura M, Takata M, Tsuruma K, Yamada M, Takahashi H, Hozumi I, Niwa J, Iguchi Y, Nikawa T, Sobue G, Inuzuka T, Hara H. Tanaka H, et al. Sci Rep. 2012;2:573. doi: 10.1038/srep00573. Epub 2012 Aug 13. Sci Rep. 2012. PMID: 22891158 Free PMC article. - Antibody-Drug Conjugates as an Emerging Therapy in Oncodermatology.
Esnault C, Schrama D, Houben R, Guyétant S, Desgranges A, Martin C, Berthon P, Viaud-Massuard MC, Touzé A, Kervarrec T, Samimi M. Esnault C, et al. Cancers (Basel). 2022 Feb 2;14(3):778. doi: 10.3390/cancers14030778. Cancers (Basel). 2022. PMID: 35159045 Free PMC article. Review. - A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal Melanoma.
Hasanov M, Rioth MJ, Kendra K, Hernandez-Aya L, Joseph RW, Williamson S, Chandra S, Shirai K, Turner CD, Lewis K, Crowley E, Moscow J, Carter B, Patel S. Hasanov M, et al. Cancers (Basel). 2020 Aug 13;12(8):2270. doi: 10.3390/cancers12082270. Cancers (Basel). 2020. PMID: 32823698 Free PMC article. - Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma.
Ott PA, Hamid O, Pavlick AC, Kluger H, Kim KB, Boasberg PD, Simantov R, Crowley E, Green JA, Hawthorne T, Davis TA, Sznol M, Hwu P. Ott PA, et al. J Clin Oncol. 2014 Nov 10;32(32):3659-66. doi: 10.1200/JCO.2013.54.8115. Epub 2014 Sep 29. J Clin Oncol. 2014. PMID: 25267741 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical